Jessica X Yu1, Melissa Oliver2, Jody Lin3, Matthew Chang4, Berkeley N Limketkai5, Roy Soetikno6, Jay Bhattacharya7, Tonya Kaltenbach8. 1. Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, California; Division of Gastroenterology and Hepatology, University of Michigan Medical School, Ann Arbor, Michigan. Electronic address: jxyu@umich.edu. 2. Department of Pediatric Rheumatology, Riley Hospital for Children, Indiana University School of Medicine, Indianapolis, Indiana. 3. Department of Pediatrics, Stanford University School of Medicine, Stanford, California. 4. Department of Gastroenterology, Kaiser Permanente-San Francisco, San Francisco, California. 5. Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, California. 6. Advanced Gastrointestinal Endoscopy, Mountain View, California. 7. Center for Primary Care and Outcomes Research, Stanford University, Stanford, California. 8. Division of Gastroenterology, San Francisco Veterans Affairs Medical Center, University of California, San Francisco, San Francisco, California.
Abstract
BACKGROUND & AIMS: Use of direct-acting oral anticoagulants (DOACs) is increasing, but little is known about the associated risks in patients undergoing colonoscopy with polypectomy. We aimed to determine the risk of post-polypectomy complications in patients prescribed DOACs. METHODS: We performed a retrospective analysis using Optum's de-identified Clinformatics Data Mart Database (2003-2016) (a de-identified administrative database from a large national insurance provider) to identify adults who underwent colonoscopy with polypectomy or endoscopic mucosal resection (EMR) from January 1, 2011, through December 31, 2015. We collected data from 11,504 patients prescribed antithrombotic agents (1590 DOAC, 3471 warfarin, and 6443 clopidogrel) and 599,983 patients not prescribed antithrombotics of interest (controls). We compared 30-day post-polypectomy complications, including gastrointestinal bleeding (GIB), cerebrovascular accident (CVA), myocardial infarction (MI), and hospital admissions, of patients prescribed DOACs, warfarin, or clopidogrel vs controls. RESULTS: Post-polypectomy complications were uncommon but occurred in a significantly higher proportion of patients receiving any antithrombotic vs controls (P < .001). The percentage of patients in the DOAC group with GIB was 0.63% (95% CI, 0.3%-1.2%) vs 0.2% (95% CI, 0.2%-0.3%) in controls. The percentage of patients with CVA in the DOAC group was 0.06% (95% CI, 0.01%-0.35%) vs 0.04% (95% CI, 0.04%-0.05%) in controls. After we adjusted for bridge anticoagulation, EMR, Charlson comorbidity index (CCI), and CHADS2 (congestive heart failure, hypertension, age over 75, diabetes, stroke [double weight]) score, patients prescribed DOACs no longer had a statistically significant increase in the odds of GIB (odds ratio [OR], 0.90; 95% CI, 0.44-1.85), CVA (OR, 0.45; 95% CI, 0.06-3.28), MI (OR, 1.07; 95% CI, 0.14-7.72), or hospital admission (OR, 0.86; 95% CI, 0.64-1.16). Clopidogrel, warfarin, bridge anticoagulation, higher CHADS2, CCI, and EMR were associated with increased odds of complications. CONCLUSION: In our retrospective analysis of a large national dataset, we found that patients prescribed DOACs did not have significantly increased adjusted odds of post-polypectomy GIB, MI, CVA, or hospital admission. Bridge anticoagulation, higher CHADS2 score, CCI, and EMR were risk factors for GIB, MI, CVA, and hospital admissions. Studies are needed to determine the optimal peri-procedural dose for high-risk patients.
BACKGROUND & AIMS: Use of direct-acting oral anticoagulants (DOACs) is increasing, but little is known about the associated risks in patients undergoing colonoscopy with polypectomy. We aimed to determine the risk of post-polypectomy complications in patients prescribed DOACs. METHODS: We performed a retrospective analysis using Optum's de-identified Clinformatics Data Mart Database (2003-2016) (a de-identified administrative database from a large national insurance provider) to identify adults who underwent colonoscopy with polypectomy or endoscopic mucosal resection (EMR) from January 1, 2011, through December 31, 2015. We collected data from 11,504 patients prescribed antithrombotic agents (1590 DOAC, 3471 warfarin, and 6443 clopidogrel) and 599,983 patients not prescribed antithrombotics of interest (controls). We compared 30-day post-polypectomy complications, including gastrointestinal bleeding (GIB), cerebrovascular accident (CVA), myocardial infarction (MI), and hospital admissions, of patients prescribed DOACs, warfarin, or clopidogrel vs controls. RESULTS: Post-polypectomy complications were uncommon but occurred in a significantly higher proportion of patients receiving any antithrombotic vs controls (P < .001). The percentage of patients in the DOAC group with GIB was 0.63% (95% CI, 0.3%-1.2%) vs 0.2% (95% CI, 0.2%-0.3%) in controls. The percentage of patients with CVA in the DOAC group was 0.06% (95% CI, 0.01%-0.35%) vs 0.04% (95% CI, 0.04%-0.05%) in controls. After we adjusted for bridge anticoagulation, EMR, Charlson comorbidity index (CCI), and CHADS2 (congestive heart failure, hypertension, age over 75, diabetes, stroke [double weight]) score, patients prescribed DOACs no longer had a statistically significant increase in the odds of GIB (odds ratio [OR], 0.90; 95% CI, 0.44-1.85), CVA (OR, 0.45; 95% CI, 0.06-3.28), MI (OR, 1.07; 95% CI, 0.14-7.72), or hospital admission (OR, 0.86; 95% CI, 0.64-1.16). Clopidogrel, warfarin, bridge anticoagulation, higher CHADS2, CCI, and EMR were associated with increased odds of complications. CONCLUSION: In our retrospective analysis of a large national dataset, we found that patients prescribed DOACs did not have significantly increased adjusted odds of post-polypectomy GIB, MI, CVA, or hospital admission. Bridge anticoagulation, higher CHADS2 score, CCI, and EMR were risk factors for GIB, MI, CVA, and hospital admissions. Studies are needed to determine the optimal peri-procedural dose for high-risk patients.
Authors: Jeong Ho Kim; Hyun Jeong Lee; Ji Won Ahn; Dae Young Cheung; Jin Il Kim; Soo-Heon Park; Jae Kwang Kim Journal: J Gastroenterol Hepatol Date: 2013-04 Impact factor: 4.029
Authors: Hyun S Kim; Tae I Kim; Won H Kim; Young-Ho Kim; Hyo J Kim; Suk-Kyun Yang; Seung-Jae Myung; Jeong-Sik Byeon; Moon S Lee; Il K Chung; Sung-Ae Jung; Yoon T Jeen; Jai H Choi; Kyu Y Choi; Hwang Choi; Dong S Han; Jae S Song Journal: Am J Gastroenterol Date: 2006-06 Impact factor: 10.864
Authors: Jeff S Healey; John Eikelboom; James Douketis; Lars Wallentin; Jonas Oldgren; Sean Yang; Ellison Themeles; Hein Heidbuchel; Hein Heidbuchle; Alvaro Avezum; Paul Reilly; Stuart J Connolly; Salim Yusuf; Michael Ezekowitz Journal: Circulation Date: 2012-06-14 Impact factor: 29.690
Authors: K Tim Buddingh; Thomas Herngreen; Jelle Haringsma; Wil C van der Zwet; Frank P Vleggaar; Ronald Breumelhof; Frank Ter Borg Journal: Am J Gastroenterol Date: 2011-01-25 Impact factor: 10.864
Authors: Christian T Ruff; Robert P Giugliano; Eugene Braunwald; Elaine B Hoffman; Naveen Deenadayalu; Michael D Ezekowitz; A John Camm; Jeffrey I Weitz; Basil S Lewis; Alexander Parkhomenko; Takeshi Yamashita; Elliott M Antman Journal: Lancet Date: 2013-12-04 Impact factor: 79.321
Authors: Hude Quan; Vijaya Sundararajan; Patricia Halfon; Andrew Fong; Bernard Burnand; Jean-Christophe Luthi; L Duncan Saunders; Cynthia A Beck; Thomas E Feasby; William A Ghali Journal: Med Care Date: 2005-11 Impact factor: 2.983
Authors: Aasma Shaukat; Steven J Mongin; Mindy S Geisser; Frank A Lederle; John H Bond; Jack S Mandel; Timothy R Church Journal: N Engl J Med Date: 2013-09-19 Impact factor: 91.245
Authors: Mahmoud Yousfi; Christopher J Gostout; Todd H Baron; Jose L Hernandez; Ray Keate; David E Fleischer; Darius Sorbi Journal: Am J Gastroenterol Date: 2004-09 Impact factor: 10.864
Authors: Linda A Feagins; Ramiz Iqbal; William V Harford; Akeel Halai; Byron L Cryer; Kerry B Dunbar; Raquel E Davila; Stuart J Spechler Journal: Clin Gastroenterol Hepatol Date: 2013-02-09 Impact factor: 11.382
Authors: Joan L Warren; Carrie N Klabunde; Angela B Mariotto; Angela Meekins; Marie Topor; Martin L Brown; David F Ransohoff Journal: Ann Intern Med Date: 2009-06-16 Impact factor: 25.391